The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.
The multicenter, randomized, double-blind, placebo-controlled study included 400 patients with symptomatic COVID-19 infection.
MOVe-OUT is a placebo-controlled, double-blind phase 2/3 study investigating the efficacy and safety of molnupiravir in non-hospitalized patients.
Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps.
Individuals with higher SAT index had lower risks for mortality, while higher IMAT index linked to higher mortality risk
So far, patient has not had any complications or signs of rejection
The Pulmonary Clinical Practice Guidelines Committee of the Cystic Fibrosis (CF) Foundation provided updated recommendations on the use of available chronic treatments for Cystic Fibrosis based on current evidence.
The test has been authorized for home use to collect nasal swab samples from individuals 2 years of age and older.
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
